ImmunityBio (IBRX) Minority Interest (2020 - 2026)

ImmunityBio (IBRX) has 7 years of Minority Interest data on file, last reported at $880000.0 in Q1 2026.

• Minority Interest for Q1 2026 came in at $880000.0, down 7.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $880000.0 (down 7.27% YoY), and the FY2025 annual result was $895000.0, down 7.64% from the prior year.
• Minority Interest declined to $880000.0 in Q1 2026 per IBRX's latest filing, from $895000.0 in the prior quarter.
• Over five years, Minority Interest peaked at $1.1 million in Q3 2023 and troughed at -$3.1 million in Q2 2023.
• A 5-year average of -$239294.1 and a median of $909000.0 in 2025 frame the typical range for Minority Interest.
• The sharpest annual moves came in 2022 and 2023: Minority Interest sank 523.95% in 2022, then soared 145.0% in 2023.
• A 5-year view of Minority Interest shows it stood at -$2.5 million in 2022, then surged by 142.12% to $1.0 million in 2023, then fell by 7.71% to $969000.0 in 2024, then slipped by 7.64% to $895000.0 in 2025, then dropped by 1.68% to $880000.0 in 2026.
• Business Quant data shows IBRX's Minority Interest at $880000.0 in Q1 2026, $895000.0 in Q4 2025, and $909000.0 in Q3 2025.